| Source: HalifaxProj (inhibit) CGL-Driver Genes |
| Type: Antiapoptotic Oncogene |
| The proteins of BCL-2 family are classified into three subgroups, i.e., the anti-apoptotic/pro-survival proteins represented by BCL-2 and BCL-XL, the pro-apoptotic proteins represented by BAX and Bak, and the pro-apoptotic BH3-only proteins represented by BAD and BID. Since the expression of Bcl-2 protein in tumor cells is much higher than that in normal cells, inhibitors targeting it have little effect on normal cells. |
| 3531- | Lyco, | Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system |
| - | in-vivo, | Nor, | NA |
| 3263- | Lyco, | Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening |
| - | in-vitro, | Nor, | H9c2 | - | in-vitro, | Stroke, | NA |
| 3277- | Lyco, | Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent |
| - | Review, | Var, | NA |
| 8414- | Lyco, | Exploring the Therapeutic Potential of Lycopene: Mechanisms, Biological Activities, and Health Benefits |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 4784- | Lyco, | Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: An update on epidemiological and mechanistic perspectives |
| - | Review, | Diabetic, | NA | - | Review, | CardioV, | NA |
| 4791- | Lyco, | Investigating into anti-cancer potential of lycopene: Molecular targets |
| - | Review, | Var, | NA |
| 4797- | Lyco, | A mechanistic updated overview on lycopene as potential anticancer agent |
| - | Review, | Var, | NA |
| 4794- | Lyco, | Anticancer Effect of Lycopene in Gastric Carcinogenesis |
| - | Review, | GC, | NA |
| 1126- | Lyco, | Lycopene Inhibits Epithelial–Mesenchymal Transition and Promotes Apoptosis in Oral Cancer via PI3K/AKT/m-TOR Signal Pathway |
| - | vitro+vivo, | Oral, | NA |
| 2533- | M-Blu, | PDT, | Methylene blue-mediated photodynamic therapy enhances apoptosis in lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 8492- | MAG, | Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway |
| - | in-vivo, | AD, | NA |
| 8497- | MAG, | Magnolol induces apoptosis in MCF-7 human breast cancer cells through G2/M phase arrest and caspase-independent pathway |
| - | in-vitro, | BC, | MCF7 |
| 1314- | MAG, | Magnolol induces apoptosis via activation of both mitochondrial and death receptor pathways in A375-S2 cells |
| - | in-vitro, | Melanoma, | A375 |
| 4534- | MAG, | Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | CRC, | COLO205 |
| 4531- | MAG, | Magnolol-induced apoptosis in HCT-116 colon cancer cells is associated with the AMP-activated protein kinase signaling pathway |
| - | in-vitro, | CRC, | HCT116 |
| 4527- | MAG, | Magnolol inhibits growth and induces apoptosis in esophagus cancer KYSE-150 cell lines via the MAP kinase pathway |
| - | in-vitro, | ESCC, | TE1 | - | in-vitro, | ESCC, | Eca109 | - | vitro+vivo, | SCC, | KYSE150 |
| 4518- | MAG, | Cisplatin, | Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells |
| - | in-vitro, | GC, | MKN45 |
| 8567- | Matr, | Matrine induces apoptosis in multiple colorectal cancer cell lines in vitro and inhibits tumour growth with minimum side effects in vivo via Bcl-2 and caspase-3 |
| - | vitro+vivo, | CRC, | NA |
| 8568- | Matr, | Matrine induces apoptosis via targeting CCR7 and enhances the effect of anticancer drugs in non-small cell lung cancer in vitro |
| - | in-vitro, | NSCLC, | A549 |
| 8574- | Matr, | Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration |
| - | in-vitro, | Lung, | A549 | - | ex-vivo, | HCC, | SMMC-7721 cell |
| 8542- | Matr, | Matrine Suppresses Lung Cancer Progression via Dual Inhibition of CHEK1-Mediated DNA Damage Repair and PI3K/AKT Survival Signaling |
| - | vitro+vivo, | Lung, | A549 |
| 8534- | Matr, | Matrine induces apoptosis and autophagy in human lung adenocarcinoma cells via upregulation of Cavin3 and suppression of PI3K/AKT pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | MRC-5 |
| 8526- | Matr, | A Systematic Review of the Pharmacology, Toxicology and Pharmacokinetics of Matrine |
| - | Review, | Nor, | NA |
| 8544- | Matr, | Matrine in Liver Diseases: Mechanistic Insights and Therapeutic Potential |
| - | Review, | BC, | NA |
| 8555- | Matr, | Matrine Exerts Pharmacological Effects Through Multiple Signaling Pathways: A Comprehensive Review |
| - | Review, | Var, | NA |
| 8546- | Matr, | Matrine Attenuates Neurological Deficits and Neuroinflammation by Inhibiting the HMGB1/RAGE Axis and Ferroptosis in Intracerebral Hemorrhage Mice |
| - | in-vivo, | Stroke, | NA |
| 8543- | Matr, | Mechanism of matrine inhibiting retinoblastoma cell growth by downregulating NR1D2 to regulate phosphorylation of the PI3K/AKT signaling pathway |
| - | in-vitro, | RPE/RB, | Y79 |
| 8655- | MBZ, | Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells |
| - | in-vitro, | Melanoma, | NA |
| 8786- | mCHEMO, | Metronomic chemotherapy in cancer treatment: new wine in an old bottle |
| - | Review, | Var, | NA |
| 8759- | MeSA, | Methylseleninic acid induces apoptosis of human bladder cancer cells through the ROS-mediated mitochondrial pathway |
| - | in-vitro, | Bladder, | J82 | - | in-vitro, | CRC, | T24/HTB-9 |
| 4112- | MF, | Novel protective effects of pulsed electromagnetic field ischemia/reperfusion injury rats |
| - | in-vivo, | Stroke, | NA |
| 496- | MF, | Low-Frequency Magnetic Fields (LF-MFs) Inhibit Proliferation by Triggering Apoptosis and Altering Cell Cycle Distribution in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | ZR-75-1 | - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MDA-MB-231 |
| 520- | MF, | Exposure to a 50-Hz magnetic field induced mitochondrial permeability transition through the ROS/GSK-3β signaling pathway |
| - | in-vitro, | Nor, | NA |
| 2259- | MFrot, | MF, | Method and apparatus for oncomagnetic treatment |
| - | in-vitro, | GBM, | NA |
| 9154- | MG, MIC-1, | Moringin, an isothiocyanate modulates multiple cellular signalling molecules in breast cancer cells |
| - | in-vitro, | BC, | NA |
| 9074- | MGF, | Mangiferin prevents the growth of gastric carcinoma by blocking the PI3K-Akt signalling pathway |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | BGC-823 |
| 9087- | MGF, | Mangiferin in human disease: Multifaceted mechanisms and applications (Review) |
| - | Review, | Var, | NA |
| 8737- | MGO, | Induction of mitochondrial apoptotic pathway in triple negative breast carcinoma cells by methylglyoxal via generation of reactive oxygen species |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | 4T1 |
| 1890- | MGO, | The Dual-Role of Methylglyoxal in Tumor Progression – Novel Therapeutic Approaches |
| - | Review, | Var, | NA |
| 1782- | MLT, | Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities |
| - | Review, | Var, | NA |
| 8669- | MLT, | Melatonin in lung cancer: integrating molecular mechanisms, tumor microenvironment regulation, apoptotic signaling, and therapeutic opportunities |
| - | Review, | Lung, | NA |
| 8662- | MLT, | Melatonin inhibits bladder tumorigenesis by suppressing PPARγ/ENO1-mediated glycolysis |
| - | vitro+vivo, | Bladder, | 5637 | - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | HNSCC, | UM-SCC-1 |
| 8689- | MLT, | Role of melatonin in Alzheimer's disease: From preclinical studies to novel melatonin-based therapies |
| - | Review, | AD, | NA |
| 8688- | MLT, | Melatonin induces apoptosis and cell cycle arrest in cervical cancer cells via inhibition of NF-κB pathway |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Cerv, | SiHa |
| 8687- | MLT, | Melatonin induces cell cycle arrest and suppresses tumor invasion in urinary bladder urothelial carcinoma |
| - | in-vitro, | CRC, | T24/HTB-9 | - | in-vitro, | Bladder, | UMUC3 |
| 8675- | MLT, | Melatonin combined with antineoplastic drugs or natural products for cancer treatment: An update |
| - | Review, | Var, | NA |
| 1063- | MLT, | HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | PC9 |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | A2058 |
| 8908- | MO, | Water Extracts of Moringa oleifera Leaves Alter Oxidative Stress-Induced Neurotoxicity in Human Neuroblastoma SH-SY5Y Cells |
| - | in-vitro, | AD, | SH-SY5Y |
| 8910- | MO, | Moringa oleifera L. leaf extract induces cell cycle arrest and mitochondrial apoptosis in Dalton's Lymphoma: An in vitro and in vivo study |
| - | vitro+vivo, | lymphoma, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:27 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid